Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$14.40 - $47.00
Next Earnings Date
May 05 2025
Next Earnings Date
May 05 2025
Latest price
Market Cap | $1.29B |
EV | $568.37M |
Shares Outstanding | 66.38M |
Beta | 1.59 |
Analyst Rating | BUY |
Analyst Target Price | $62.08 |
P/E 2025E | - |
P/Revenue 2025E | 293.01x |
Revenue | 14.70% |
EPS | -14.30% |
Operating Cash Flow | -37.30% |
Free Cash Flow | -37.00% |
Revenue | 84.50% |
EPS | -15.90% |
Operating Cash Flow | -17.90% |
Free Cash Flow | -14.50% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -5109.09% |
ROE 2025E | -31.03% |
ROCE 2024 | -26.84% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Celldex Therapeutics, Inc.
CLDX
Sector
Healthcare
Industry
Biotechnology
CEO
Marucci, Anthony
Employees
186
Website
www.celldex.comIPO Date
1986-05-15
Headquarters
Perryville III Building, Suite 220, 53 Frontage Road, Hampton, New Jersey, 08827, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved